Exhibit 99.1

Press / Investor Contact:

Bonnie Ortega

Director, Investor/Public Relations

Cardium Therapeutics, Inc.

Tel: (858) 436-1018

Email: InvestorRelations@cardiumthx.com

CARDIUM REPORTS ON EXCHANGE LISTING DEFICIENCY AND COMPLIANCE PLAN

SAN DIEGO, CA – December 2, 2010 – Cardium Therapeutics (NYSE Amex: CXM) reported on a communication from the staff of the company’s current listing exchange indicating that it considered the company to be noncompliant with one of the listing requirements of the NYSE Amex LLC, based on its quarterly report for the period ended September 30, 2010, and providing that the company should submit a plan that would reestablish compliance with the listing requirement by August 26, 2011. The company reported that it has submitted a plan designed to reestablish compliance with the exchange’s requirement in advance of the August 26, 2011 timeframe.

Based on the company’s quarterly report on Form 10-Q for the period ended September 30, 2010, noncompliance was noted with respect to the requirement for minimum “stockholders’ equity” of $6.0 Million pursuant to section 1003(a)(iii) of the exchange’s company guide. As reported, the recently revised accounting treatment of certain derivative liabilities that are associated with valuation estimates of unexercised but outstanding variable-priced warrants reduced the calculation of stockholders’ equity by $3.5 Million (i.e. to $4.6 Million when it would otherwise have been $8.1 Million without the estimated derivative liability). The exchange indicated that in order to maintain its listing, a plan should be submitted by December 27, 2010 addressing how the company intends to regain compliance with Section 1003(a)(iii) of the exchange’s company guide by August 26, 2011. The company reported today that it has submitted a plan designed to reestablish its compliance with the listing requirement.

The communication and compliance plan has no current effect on the listing of the company’s shares on the exchange. If the plan is not acceptable or the company does not make sufficient progress under the plan or reestablish compliance by August 26, 2011, then the exchange would be expected to initiate delisting proceedings. If the company’s common stock was ultimately delisted from the exchange, it would be expected to trade on the OTC Bulletin Board, a regulated quotation service that provides quotes, sale prices and volume information in over-thecounter equity securities. The company’s common stock was traded on the OTC Bulletin Board until July 2007, when the company elected to instead list its shares on the American Stock Exchange.

-1-

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the company’s plan for regaining compliance with exchange listing requirements will be acceptable or that it will make sufficient progress under the plan or ultimately achieve compliance, that results observed in one study or using one type of product or procedure will be replicated in subsequent studies or in studies using newly-developed products or procedures, that planned product development efforts and clinical studies can be performed in an efficient and effective manner, that regulatory approvals can be obtained in a timely manner or at all, that partnering, distribution or other commercialization efforts can be achieved, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of biologics, medical devices and other products, and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new products and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2010 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics^TM Generx^® and MedPodium^TM are trademarks of Cardium Therapeutics, Inc.

Tissue Repair^TM, Gene Activated Matrix^TM, GAM^TM, Excellagen^TM, Excellarate^TM, Osteorate^TM, Appexium^TM and Lińee^TM

are trademarks of Tissue Repair Company.

-2-